课题基金 / 基金详情

项目摘要

项目成果

Djade Ibrahim Soumana的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):慢性肝病每年在美国造成约1000人死亡,其中40%的病例由丙型肝炎病毒引起。该病毒具有正链RNA作为其基因组和用于基因组复制的高度易错的NS 5 B RNA依赖性RNA聚合酶。因此,HCV已迅速演变为6种基因型和超过14种亚型。人们已经做出了很大的努力来开发有效的直接作用的抗病毒药物(DAA),然而,由于专注于西方国家最主要的基因型1a,我们忽略了大约30%的HCV感染者,而且,在第三世界国家发现的受害者。该病毒的异质性已经清楚地限制了泛基因型DAA的发现。话虽如此,我建议通过了解最不同的HCV NS 3/4A蛋白酶的底物识别差异,我们可以更接近设计满足两个主要特性的抑制剂:1)抑制剂必须适合所有HCV NS 3/4A蛋白酶的整体底物包膜; 2)抑制剂必须表现出非常低的耐药性敏感性。为此,将确定来自不同基因型的HCV NS 3/4A的蛋白酶结构域与其天然底物和抑制剂的复合物的晶体结构。
英文摘要
DESCRIPTION (provided by applicant): Chronic liver disease kills an estimated 1000 people in the US every year and is caused in 40 percent of cases, by the hepatitis C virus. This virus has a positive strand RNA as its genome and a highly error prone NS5B RNA-dependent RNA polymerase for genomic replication. As a consequence, HCV has rapidly evolved with six genotypes and more than 14 sub-genotypes. Great efforts have been made to develop effective direct acting antivirals (DAA), however, by focusing on genotype 1a, the most predominant in western countries, we have neglected about 30 percent of people infected with HCV and moreover, victims found in third world countries. The heterogeneity of the virus has clearly set limitations to the discovery of a pan-genotypic DAA. That being said, I propose that by understanding the differences in substrate recognition of the most divergent HCV NS3/4A protease, we can get one step closer to designing an inhibitor that satisfies two major properties: 1) the inhibitor must fit within the overall substrate envelope of all HCV NS3/4A protease; 2) the inhibitor must exhibit a very low susceptibility to drug resistance. To that end, crystal structures of the protease domain of HCV NS3/4A from various genotypes will be determined in complex with their natural substrates and inhibitors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HCV protease: from atomic mechanism for drug resistance to novel drug design
HCV protease: from atomic mechanism for drug resistance to novel drug design
海外基金